Evoked adipose inflammation and insulin resistance in humans

Experimental Endotoxemia Induces Adipose Inflammation and Insulin Resistance in Humans

Short title: Evoked adipose inflammation and insulin resistance in humans

Nehal N. Mehta¹²³, Fiona C. McGillicuddy¹², Paul D. Anderson⁴, Christine C. Hinkle¹², Rachana Shah³, Leticia Pruscino¹², Jennifer Tabita-Martinez¹, Kim F. Sellers⁵, Michael R. Rickels²³, Muredach P. Reilly¹²³

¹The Cardiovascular Institute, ²The Institute for Translational Medicine and Therapeutics, ³Institute for Diabetes Obesity and Metabolism, University of Pennsylvania School of Medicine Philadelphia, PA; ⁴Dartmouth Hitchcock Medical Center; Lebanon, NH; ⁵Georgetown Medical School, Washington D.C.

Address for Correspondence:
Muredach P. Reilly
E-mail: muredach@spirit.gerc.upenn.edu

Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournals.org

Submitted 10 March 2009 and accepted 3 September 2009.

This is an uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association, publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org.
**Objective:** An emerging model of metabolic syndrome and type-2 diabetes is of adipose dysfunction with leukocyte recruitment into adipose leading to chronic inflammation and insulin resistance (IR). This study sought to explore potential mechanisms of inflammatory-induced IR in humans with a focus on adipose tissue.

**Research Design and Methods:** We performed a sixty-hour endotoxemia protocol (3 ng/kg intravenous bolus) in healthy adults (N=20, 50% male, 80% Caucasian, age 27.3±4.8). Before and after endotoxin, whole blood sampling, subcutaneous adipose biopsies, and frequently-sampled intravenous glucose tolerance (FSIGT) testing were performed. The primary outcome was the FSIGT insulin sensitivity index (SI). Secondary measures included inflammatory and metabolic markers, and whole blood and adipose mRNA and protein expression.

**Results:** Endotoxemia induced systemic IR as demonstrated by a 35% decrease in SI (3.17 ± 1.66 to 2.06 ± 0.73 x 10^{-4} (µU/ml)^{-1}·min^{-1}, p<0.005) while there was no effect on pancreatic beta-cell function. In adipose, endotoxemia suppressed insulin receptor substrate-1 and markedly induced suppressor of cytokine signaling (SOCS) proteins (1 and 3) coincident with local activation of innate (IL-6, TNF) and adaptive (monocyte chemoattractant protein-1 and CXCL10 chemokines) inflammation. These changes are known to attenuate insulin receptor signaling in model systems.

**Conclusions:** We demonstrate, for the first time in humans, that acute inflammation induces systemic IR following modulation of specific adipose inflammatory and insulin signaling pathways. It also provides a rationale for focused mechanistic studies and a model for human proof-of-concept trials of novel therapeutics targeting adipose inflammation in IR and related consequences in humans.
Adipose dysfunction, insulin resistance (IR) and type-2 diabetes (T2D) are pro-inflammatory states. Indeed, gene manipulation of toll like receptors [1, 2], chemokines [3, 4] and cytokines in experimental models has defined a role of innate and adaptive immunity in diet induced adipose dysfunction and IR. An emerging model is one of early adipose recruitment of T-cells and macrophages with adipocyte inflammation and resistance to insulin promoting metabolic syndrome, T2D and atherosclerosis.

Experimental data suggest that inflammation may attenuate adipocyte insulin signaling. Dietary and inflammatory activation of the inhibitor of nuclear factor kappa B kinase beta subunit (IKKβ), c-Jun amino terminal kinase (JNK) [5], protein kinase C (PKC) [6] and janus tyrosine kinases (JAK) / signal transducers and activators of transcription (STAT) [7] have been implicated in IR in adipocytes and rodent experimental models [7]. These inflammatory kinases may promote IR by downregulating components of the insulin signaling cascade, including the insulin receptor and insulin receptor substrates (IRSs), and by inducing suppressors of cytokine signaling (SOCS), inhibitors of insulin receptor signaling. Despite substantial data in animal models, however, little is known of the specific role and mechanisms of inflammatory IR in humans. Defining whether adipose inflammation occurs in human IR and which specific pathways are involved will provide greater insight into human pathophysiology and inform preventive and therapeutic strategies for T2D and its complications.

We and others utilize low-dose experimental endotoxemia to activate toll-like receptor 4 (TLR-4) signaling in vivo as a model of inflammation-induced metabolic disturbances in humans [8-10]. Here, we define the effects of endotoxemia on insulin sensitivity and focus on adipose inflammation because of its emerging relevance in dietary excess and adipose dysfunction in human IR. We demonstrate for the first time in humans that activation of innate immunity in vivo induces IR following modulation of specific adipose inflammatory and insulin signaling pathways.

METHODS

Human Subjects Study Protocol. Healthy volunteers were recruited from the general population of the Delaware Valley [10], the protocol was approved by the Institutional Review Board of the University of Pennsylvania (Penn) and subjects gave written informed consent. Full details are described in the online supplement which is available at http://diabetes.diabetesjournals.org. Briefly, criteria included healthy men or non-pregnant/lactating women, aged 18-40, with body mass index (BMI) of 18-30. Twenty subjects were recruited, equally divided by gender, to Penn’s Clinical Translational Research Center (CTRC) for three visits: Visit 1 for screening; Visit 2, two weeks later, for frequently sampled intravenous glucose tolerance (FSIGT) testing and dietary counseling; and Visit 3 consisting of an overnight acclimatization phase, a 24-hour saline control phase, and a 24-hour post-LPS study phase (60-hours total). Lipopolysaccharide (US standard reference endotoxin, lot # CC-RE-LOT-1+2; Clinical Center, Pharmacy Department at the National Institutes of Health) was given intravenously as a 3 ng/kg bolus at 6AM on day 2. Blood samples (9 before and 9 after LPS) and subcutaneous gluteal adipose aspiration-biopsy samples (before, and 4, 12, 24 hrs after LPS) were collected (in n=17 participants;
Evoked adipose inflammation and insulin resistance in humans

621.4 +/- 253.1 mg average weight per sample).

Laboratory Measures. Two-weeks prior to LPS and 24 hours following LPS, the insulin sensitivity index (SI) was derived from a frequently-sampled intravenous glucose tolerance (FSIGT) test. We chose the 24-hours post-LPS because we expected IR to be established by this time-point based on human and animal experimental and observational data [8, 10-12] and because of practical considerations given the experimental design. We chose FSIGT as the method for determining insulin sensitivity because the test also provides a measure of pancreatic beta-cell function, the acute insulin response to glucose (AIRg), and so allows assessment of endotoxemia effects on the beta-cell. The FSIGT test was conducted using the insulin-modified approach as previously described [13]. SI was derived from Bergman's minimal model [14] using MINMOD Millennium software [15]. AIRg was calculated as the incremental area-under-the-curve for insulin from t=0 to 10 min [12]. Complementary estimates of IR and beta-cell function, the homeostasis model assessment for IR, HOMA-IR index [glucose (mmol/L) x insulin (µU/mL)/22.5] and the HOMA for beta-cell function, HOMA-B index [insulin (µU/mL) x 20/glucose (mmol/L) – 3.5], were calculated using fasting glucose and insulin values at 24 hours and 5 min before and 24 hours after LPS. Plasma biomarkers and lipoproteins measurement was described previously [10] and is outlined in the online supplement.

RNA isolation, real-time PCR quantification of mRNAs and adipose protein isolation for Western blotting are described in detail in the online supplement. RNA extraction was performed for measurement of mRNA levels of interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF), tumor necrosis factor induced protein 3 (A20), resistin, suppressor of cytokine signaling (SOCS)-1, SOCS-2, SOCS-3, SOCS-6, insulin receptor, insulin receptor substrate (IRS)-1, IRS-2, IRS-3, IRS-4, GLUT-4, MCP-1 and chemokine CXCL10 mRNA (supplement Table 1). Macrophage marker human epidermal growth factor module-containing mucin-like receptor 1 (EMR1-F4/80) mRNA also was assayed in adipose.

Statistical Analysis. Data are reported as mean±SEM for continuous variables, and as proportions for categorical variables. In general, the effect of endotoxemia on plasma biomarkers, metabolic measures, blood and adipose mRNAs, and adipose protein levels were tested by mixed effects modeling or repeated measures analysis of variance (ANOVA). For plasma data, we considered the time-matched difference (after minus before for matched time points prior to and following LPS) in biomarker responses and used a mixed effects model to consider the effect due to LPS. A variety of models including linear, quadratic, and cubic polynomial were fit and the best fit for each variable was used for final analyses; e.g., quadratic models for TNF, IL-6, resistin. A similar time matched mixed effect modeling approach was applied to whole blood mRNA data. Repeated-measures ANOVA was applied to FSIGT data (SI and AIRg), HOMA data (HOMA-IR and HOMA-B) and adipose mRNA data. When significant global differences were found in ANOVA, post hoc paired t-tests were used to compare time-points. Analyses were performed using the freeware statistical package, R (Version 2.4.1; Copyright (C) 2006 The R Foundation for Statistical Computing). Statistical significance was defined as a p-value <0.05.

RESULTS

Baseline characteristics of participants and clinical responses to endotoxemia. Participants were healthy adults volunteers (N=20, 50% male, 80% Caucasian, age 25.7±3.9). They had normal
blood pressure, plasma lipoproteins, BMI and body fat distribution (Table 1), and baseline SI and HOMA-IR were consistent with data from healthy subjects published by our group [13]. Endotoxemia produced a transient febrile illness in all subjects with increases in temperature, heart rate and white blood cell count largely resolving by 8-12 hours following LPS (Table 2).

Systemic inflammatory and metabolic responses. We have previously described plasma adipokine responses in this study sample [10]. Briefly, endotoxemia induced a marked, rapid and transient induction of plasma TNF and IL-6 (Table 2), followed by a robust increase in circulating resistin, and a delayed but significant increase in leptin and leptin-soluble leptin ratio in plasma. We now report significant increases in additional circulating inflammatory markers including MCP-1 and hs-CRP (Figure 1A) as well as plasma cortisol and in free fatty acids, with a trend towards increased growth hormone (p=0.08) levels (Figure 1B). Overall, these findings confirm a transient inflammatory response during human endotoxemia with modulation of several inflammatory, adipokine and hormonal cascades that are known to impact insulin sensitivity.

Experimental endotoxemia induces insulin resistance in humans. We hypothesized that these inflammatory and metabolic perturbations would induce IR without altering pancreatic beta-cell function. Insulin sensitivity, measured as SI, declined by over 30% from two weeks prior to 24-hrs after LPS (3.17±1.66 to 2.06 x 10^{-4} µU·ml^{-1}·min^{-1}, p<0.005) (Figure 2A). In contrast, AIRg, a measure of pancreatic beta-cell function, showed no change following LPS (711±418 to 744±488 µU·ml^{-1}·min, p=0.7) (Figure 2B). Consistent with the FSIGT data, HOMA-IR was 39% and 46% higher at 24 hrs after LPS (2.17±0.83) than 24-hours (1.56±0.62; p<0.001) and 5 minutes (1.49±0.63; p<0.001) prior to LPS (Figure 2C) while HOMA-B, an estimate of pancreatic beta-cell function, was not influenced by the endotoxemia state (p=0.81) (Figure 2D). We observed a modest negative correlation (Spearman R = -0.51) between HOMA-IR and SI consistent with prior work highlighting the differences in fasting vs. evoked physiology captured by these indices [16].

We explored whether peak levels of inflammatory and metabolic biomarkers (TNF, IL-6, MCP-1, hs-CRP, resistin, cortisol, GH or FFA) correlated with the degree of induced IR. We found that peak hs-CRP (spearman r=0.57, p<0.03) and resistin (r=0.47, p=0.08) tended to correlate with change in HOMA-IR, a measure of hepatic IR, while the peak FFA levels were inversely correlated (r=-0.81, p=0.004) with SI, a measure of peripheral insulin sensitivity.

Endotoxemia induces adipose inflammation in humans. Endotoxemia induced a robust innate inflammatory response in adipose with increases in mRNA levels of IL-6 (peak 110-fold, ANOVA F=64.5, p<0.001), TNF (peak 6-fold, F=4.9, p<0.001) and A20 (peak 11-fold, F=79.7, p<0.001) (Figure 3A). In parallel, adipose mRNA levels of MCP-1 (peak 30-fold, F=3.49, p=0.03), a chemokine implicated in adipose macrophage recruitment [3, 4], and CXCL10 (peak 15-fold, F=8.5, p<0.005), a T-cell chemokine, were markedly induced during endotoxemia (Figure 3B). Supporting these mRNA changes, protein levels of both A20 and MCP-1 were significantly increased in adipose at Western blotting (Figure 3C). Remarkably, adipose mRNA levels of resistin (4-fold, F=6.9, p<0.001), a leukocyte-derived cytokine in humans, and EMR1-F4/80 (peak 13-fold, F=13.8, p<0.001), a macrophage marker, were increased suggesting recruitment of leukocytes to adipose during endotoxemia.
Endotoxemia modulates the insulin signaling pathway in adipose and blood. We sought evidence that adipose inflammation modulated insulin signaling pathways in adipose. SOCS family proteins inhibit tyrosine kinase receptor signaling including the insulin receptor. At baseline prior to LPS, SOCS-3, SOCS-6 and SOCS-2 mRNAs were the most abundant in human adipose with evidence of differential expression compared to whole blood (Supplement Table 2). Following endotoxin, adipose SOCS-1 (10-fold) and SOCS-3 (20-fold), but not SOCS-2 or SOCS-6, mRNAs increased markedly (Figure 4A). There were similar striking changes in whole blood SOCS-1 and SOCS-3 (3-fold and 30-fold, respectively) but endotoxin actually reduced SOCS-2 and SOCS-6 mRNA in blood (Figure 4B).

Insulin receptor substrate (IRS) family members are key mediators of cellular insulin signaling. Prior to LPS, we detected mRNA for IRS-1 and IRS-2 but not IRS-3 or IRS-4 in adipose with differential expression compared to whole blood (Supplement Table 2). Endotoxin reduced IRS-1 (by 47%) mRNA in adipose. In whole blood, IRS-1 mRNA levels also fell (by 53%), but IRS-2 mRNA increased (2.3 fold increase) (Table 3). In parallel, insulin receptor mRNA levels decreased significantly in blood but not in adipose, and there was no significant change in GLUT-4 mRNA in adipose or whole blood (Table 3). Western blotting of adipose proteins generally supported mRNA data with reduction in IRS-1, no change in insulin receptor; however, GLUT-4 protein levels tended to fall (Figure 5). Furthermore, enhanced serine phosphorylation of AKT, with no change in total AKT (Figure 5), was observed consistent with previous findings of TNF-induced serine phosphorylation of AKT in adipocytes [17]. Overall, endotoxemia induced specific SOCS proteins and modulated several components of the insulin signaling pathway in adipose.

DISCUSSION

Inflammation, particularly in adipose tissue, has been implicated in diet and obesity related IR in experimental models. Resistance to insulin also occurs acutely in human states of infection and sepsis. However, the specific mechanisms and the potential for therapeutic targeting in humans are poorly understood. In this work, we found that endotoxemia induced systemic IR but not pancreatic beta-cell dysfunction in humans. Further, IR measured at 24-hrs post-LPS was preceded by specific modulation of adipose inflammatory and insulin signaling pathways. This work defines specific targets for inflammatory modulation of insulin signalling in humans and also provides a human model for proof-of-concept studies of novel therapeutics in IR and its complications.

Epidemiological studies suggest causal links between chronic inflammation, IR and incident T2D [18, 19] while observational data demonstrate that IR and overt type-2 diabetes may emerge during human infections and sepsis [11]. Agwunobi and colleagues were the first to show impaired insulin sensitivity 6-7 hours following LPS administration utilizing euglycemic clamp studies [8]. Our study goes beyond the findings of Agwunobi by demonstrating persistence of IR at 24 hours after endotoxin in the absence of any effect on pancreatic beta cell function while also identifying adipose tissue inflammatory responses and modulation of specific adipose insulin signaling proteins that precede systemic IR. Interestingly, Agwunobi also noted enhanced insulin sensitivity 2 h after LPS as determined by a significant increase in the glucose infusion rate required during the clamp. A recent elegant study [20] employing isotope tracers with a euglycemic clamp showed that this acute and transient
increase in insulin sensitivity at 1-2 hours after LPS was due to increases in both hepatic and peripheral insulin sensitivity.

Experimental models support an important role for innate and adaptive immunity in diet and obesity induced IR [1, 3-5, 21]. Deficiency of TLR-4, the innate antigen/LPS receptor, protects against diet induced obesity and IR in rodents [2]. TNF impairs insulin-mediated glucose disposal and functional TNF deficiency in mice protects from obesity-induced IR [21]. However, the relevance to human pathophysiology of individual signalling pathways implicated in rodent models remains unknown. In fact, species heterogeneity in inflammatory modulation [22] and of insulin signalling has been documented [9, 23]. Thus, use of human models of inflammation can provide unique insight into clinically relevant mechanisms and therapeutic targets for IR and type-2 diabetes.

Our study is the first to demonstrate loss of insulin sensitivity without any apparent effect on pancreatic beta-cell function during acute human inflammation. Because fasting-based HOMA-IR estimates have been shown to correlate best with measures of hepatic insulin sensitivity and FSIGT SI with measures of peripheral insulin sensitivity [24], endotoxemia appears to trigger both hepatic and peripheral insulin resistance. Indeed, we note that Agwunobi [8] has published data with euglycemic clamps which demonstrate hepatic IR following LPS. Further, we describe several inflammatory perturbations that may impact tissue and systemic insulin sensitivity - induction of inflammatory cytokines and chemokines, modulation of adipokine signalling [10], activation of the hypothalamic-pituitary-adrenal axis [25], and altered flux of plasma free-fatty acids [26]. Indeed, the degree of evoked change in several inflammatory and metabolic markers, including free fatty acids, hs-CRP, resistin, and growth hormone tended to precede and correlate with the degree of IR. Taken together, therefore, these data support a model of both hepatic and peripheral IR during endotoxemia – with peripheral IR likely to be occurring at the level of skeletal muscle as well as adipose tissue.

Recent experimental studies in rodents demonstrated that adipose recruitment of T-cell and macrophages in obesity promotes adipocyte inflammation leading to local and systemic IR [27]. We hypothesized that adipose inflammation would be a consequence of human endotoxemia that might contribute to local and systemic IR. Endotoxemia induced a rapid and transient increase in adipose TNF and IL-6. There was also a marked induction of adipose MCP-1 which is known to recruit CCR-2 expressing monocytes, increase inflammatory-M1 adipose tissue macrophage (ATM) and promote IR [27] . Recent studies of diet induced obesity suggest that upregulation of T-cell chemokines in adipose and recruitment of inflammatory TH1 cells precedes recruitment of monocytes and the development of systemic IR. Remarkably, we found that endotoxemia induced CXCL10, a potent T-cell chemokine. The emergence of resistin mRNA in adipose suggests leukocyte recruitment because expression of this adipokine is restricted to myeloid lineage in humans [23]. In addition, we found increased mRNA levels of the macrophage marker, EMR1-F4/80 [28], in adipose further supporting that endotoxemia may promote adipose recruitment of macrophages. Overall, these data suggest that endotoxemia induces human adipose inflammatory responses similar to those observed in models of diet and obesity-related IR [1-4, 21, 27].

Whether inflammation attenuates adipose insulin signaling in humans and which signaling pathways are involved has not been defined. Several inflammatory adipokines such as TNF, IL-6 and resistin, as well as endotoxin itself, induce SOCS
proteins which inhibit insulin receptor signaling and target IRS proteins for ubiquitination and proteosomal degradation [29, 30]. The SOCS family, consisting of eight members, is recognized as a general negative feedback mechanism for receptor tyrosine kinase signaling including the insulin receptor. Using the yeast two hybrid system, SOCS-1, 3, 6 have been shown to bind to the insulin receptor [31], and cells from SOCS-1 deficient mice exhibit enhanced insulin sensitivity [30]. Conversely, in obesity, SOCS-1 and SOCS-3 are increased in liver, muscle and fat coincident with reduced tyrosine phosphorylation of IRS proteins. We report for the first time the pattern of SOCS family mRNA expression in human adipose and a marked and selective induction of adipose SOCS proteins during endotoxemia; SOCS-1 and SOCS-3 were increased with no effect of SOCS-2 and SOCS-6. Our findings suggest that induction of SOCS-3 in adipose may be an important molecular mechanism of IR in human inflammatory states [31].

The in vivo effect of inflammation on insulin receptor signaling in human adipose is unknown. The insulin receptor, a transmembrane dimeric protein with intrinsic kinase activity, recruits IRS proteins upon insulin binding. Tyrosine phosphorylation of IRS proteins activates phosphatidylinositol-3-kinase (PI3K) leading to AKT phosphorylation and GLUT-4 mobilization [32]. Inflammatory kinases including IKKβ [5, 33], JNK [5], PKCs [6] and JAK-STATs attenuate insulin signaling in adipocytes and in rodent models. These kinases induce serine-phosphorylation of IRS-1 which inhibits IRS-1 tyrosine-phosphorylation during insulin signaling [32]. We found tissue specific IRS expression and down-regulation of adipose IRS-1 protein coincident with reduced IRS-1 mRNA. Our data also suggest species heterogeneity in the pattern of adipose IRS expression with more abundant IRS-2 in human adipose compared to that reported in rodents [32]. The effect of endotoxemia on IRS-1 protein levels is one of several mechanisms by which endotoxemia may impair insulin signaling in human adipose. Remarkably, changes in several mRNAs in whole blood paralleled that in adipose (e.g., IL-6, MCP1, SOCS1 and 3). However, inflammation appears to modulate specific insulin signaling related proteins (insulin receptor, SOCS2 and 6, IRS-2) in a tissue specific manner. This should prompt caution in extrapolating tissue specific effects from global characterization of whole blood mRNAs.

Overall, endotoxemia induces IR in humans following modulation of adipose tissue inflammatory and insulin signal pathways in vivo. While adipose dysfunction in genetically and environmentally susceptible patients may increase inflammation, experimental endotoxemia may also induce adipose inflammation and subsequent adipocyte dysfunction which then leads to IR. However, our study has several limitations. While we have not definitively proven that adipose inflammation is causal in systemic IR during endotoxemia, our work provides proof-of-principle that inflammation-induced systemic IR emerges after inflammatory modulation of adipose insulin signaling in humans. We emphasize the need for specific study of the chronic low-grade human inflammation observed in obesity, metabolic syndrome and T2D. Our approach to study insulin sensitivity using the FISGT-derived SI at 24 hours post-LPS is limited in that we cannot differentiate various contributions of changes in hepatic and peripheral insulin sensitivity versus the total body change and cannot define the kinetics of the development and resolution of IR. However, we utilized the FSIGT SI as a sensitive measure of peripheral IR and combined this with the HOMA-IR which correlates best with measures of hepatic insulin sensitivity [24]. Furthermore, FSIGT
enabled examination of whether pancreatic beta-cell function changes during inflammation-induced IR, while the hyperinsulinemic euglycemic clamp does not. We acknowledge that inflammatory effects are likely to occur in liver and in skeletal muscle during endotoxemia and that these could impact systemic IR. Indeed, our HOMA-IR data and our FSIGT data support both hepatic and peripheral IR consistent with published euglycemic clamp studies. Detailed examination of changes in skeletal muscle and greater study of adipose tissue inflammation and function in relationship to the kinetics of IR is warranted in future studies. Despite these limitations, our study provides the first tissue level data on evoked inflammatory pathways in human IR.

Finally, endotoxemia may not represent accurately the pathophysiology of chronic inflammatory, insulin resistant disease states. Several lines of evidence, however, support its relevance to the pathophysiology of IR in humans. First, an inflammatory IR and metabolic dyslipidemia emerges clinically during acute sepsis [11] and chronic infections [34]. Second, we and others have shown that cytokine/adipokine [10, 23, 35], acute phase reactant responses and lipoprotein changes [36, 37] observed acutely during experimental endotoxemia resemble those chronically observed in the metabolic syndrome. Third, gene manipulation and drug targeting of the TLR-4 [2, 38] and NFKB [5, 39] have provided proof of concept that modulation of innate immune signaling attenuates IR and type-2 diabetes in dietary and obesity models. Last, and directly relevant to the effect on adipose, we recently demonstrated that endotoxemia induces gene expression responses in subcutaneous adipose [40] that are remarkably similar to the changes observed in visceral adipose in insulin resistant states [41-43].

CONCLUSION

Human endotoxemia induces systemic IR, but not pancreatic beta-cell dysfunction. Remarkably, evoked adipose inflammation and modulation of adipose insulin signal pathways, similar to some of those described in rodent models of diet induced obesity and IR, precedes the emergence of systemic IR in humans. Our findings suggest specific targets in humans which warrant further mechanistic focus. For example, induction of specific SOCS proteins and down-regulation of IRS1 are likely to play roles in the inflammatory induction of adipose and systemic IR in humans. This work also provides a human experimental model for studies of novel therapeutics targeting systemic and adipose inflammation in IR and its metabolic consequences.

ACKNOWLEDGEMENTS

This work was supported by a Clinical and Translational Science Award (RFA-RM-06-002) from the National Center for Research Resources (NCRR), by R01 HL-073278 (MR), P50 HL-083799-SCCOR (MR) and W.W. Smith Charitable Trust (#H0204) (MR). Dr. Mehta is a recipient of the ACC Young Investigator Award for the Metabolic Syndrome.
Evoked adipose inflammation and insulin resistance in humans

REFERENCES


Evoked adipose inflammation and insulin resistance in humans

11


FIGURE LEGENDS

Figure 1: Plasma levels of inflammatory and hormonal markers. (A) Endotoxemia increased plasma tumor necrosis factor alpha (TNF), monocyte chemoattractant protein-1 (MCP-1) and hs-C reactive protein (hs-CRP). (B) Plasma cortisol and free fatty acids increased significantly with a trend for increase in growth hormone (p=0.08). Inset graphs show the difference for 24 hours after vs. 24 hours before LPS. *p<0.0001 and †p<0.005 in mixed effects model.

Figure 2. Endotoxemia induced insulin resistance without change in pancreatic beta-cell function. (A) Endotoxemia suppressed the insulin sensitivity index (SI) at frequently sampled intravenous glucose tolerance (FSIGT) testing whereas (B) there was no change in the FSIGT test-derived acute insulin response to glucose (AIRg), a measure of pancreatic beta-cell function. (C) Consistent with this, the homeostatic model assessment (HOMA) of insulin resistance fell following LPS while (D) the HOMA-B estimate of beta-cell function was unchanged. *p<0.001 in mixed effects model.

Figure 3. Endotoxemia induced adipose inflammation in humans. (A) Endotoxemia increased adipose interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF) and tumor necrosis factor induced protein 3 (A20) mRNA levels. (B) In parallel, mRNA levels of monocyte chemoattractant protein-1 (MCP-1) and CXCL10, monocyte and T-cell chemokines were induced. (C) Western blotting confirmed increases in adipose A20 and MCP-1 proteins (representative blot shown; densitometry N=3; *ANOVA p<0.05).

Figure 4. Differential modulation of adipose and whole-blood suppressor of cytokine signaling (SOCS) proteins. Endotoxemia induced adipose and whole-blood mRNA levels of (A) SOCS-1 and (B) SOCS-3, but not (C) SOCS-2 and (D) SOCS-6. *p<0.0001 in ANOVA (adipose) or mixed effects model (blood).

Figure 5. Western blot of insulin signaling proteins in adipose tissue. Relative to beta-actin, endotoxin reduced protein levels of IRS-1 and GLUT-4, increased phosphorylated-AKT and had no effect on insulin receptor expression (representative blot shown; densitometry for IRS-1 and pAKT N=3; *ANOVA p<0.01).
Table 1. Baseline Characteristics of Study Participants.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mean (±SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>25.7 (3.90)</td>
</tr>
<tr>
<td>Blood pressure</td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>116 (15)</td>
</tr>
<tr>
<td>Diastolic</td>
<td>67 (8)</td>
</tr>
<tr>
<td>Total Cholesterol (mmol/L)</td>
<td>4.53 (0.52)</td>
</tr>
<tr>
<td>HDL Cholesterol (mmol/L)</td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>1.33 (0.26)</td>
</tr>
<tr>
<td>Females</td>
<td>1.69 (0.34)</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>0.86 (0.39)</td>
</tr>
<tr>
<td>Fasting Glucose (mmol/L)</td>
<td>4.68 (0.28)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>24.27 (1.62)</td>
</tr>
<tr>
<td>Females</td>
<td>23.37 (0.78)</td>
</tr>
<tr>
<td>Waist Circumference (cm)</td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>83.9 (5.81)</td>
</tr>
<tr>
<td>Females</td>
<td>82.8 (5.1)</td>
</tr>
<tr>
<td>^Total Body Fat DEXA (%)</td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>15.3 (3.4)</td>
</tr>
<tr>
<td>Females</td>
<td>29.7 (3.3)</td>
</tr>
<tr>
<td>*FSIGT-insulin sensitivity index (SI, x 10⁴ (µU/ml)⁻¹·min⁻¹)</td>
<td>3.17 (1.66)</td>
</tr>
<tr>
<td>†HOMA-IR insulin resistance index</td>
<td>1.56 (0.63)</td>
</tr>
<tr>
<td>*FSIGT-acute insulin response to glucose (AIRg, µU·ml⁻¹·min)</td>
<td>701 (120)</td>
</tr>
<tr>
<td>†HOMA-B beta-cell function index</td>
<td>104 (36)</td>
</tr>
</tbody>
</table>

^DEXA = Dual energy X-ray absorptometry. *FSIGT = Frequently Sampled Intravenous Glucose Tolerance test. † HOMA = Homeostatic Model Assessment

Table 2. Peak Clinical and Systemic Inflammatory Responses during Endotoxemia

<table>
<thead>
<tr>
<th></th>
<th>Pre-LPS</th>
<th>Post-LPS</th>
<th>Time of Peak</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma IL-6 (ng/mL)</td>
<td>3.2 (±17.1)</td>
<td>*1607 (±650)</td>
<td>2 hours</td>
</tr>
<tr>
<td>Plasma TNF (ng/mL)</td>
<td>3.0 (±1.1)</td>
<td>*507 (±251)</td>
<td>2 hours</td>
</tr>
<tr>
<td>Heart rate (beat per min)</td>
<td>83 (±11)</td>
<td>103 (±14)</td>
<td>4 hours</td>
</tr>
<tr>
<td>Temperature (degrees Celsius)</td>
<td>36.5 (±0.5)</td>
<td>†37.7 (±1.0)</td>
<td>4 hours</td>
</tr>
<tr>
<td>White blood cell count (mg/UL)</td>
<td>6.5 (±0.9)</td>
<td>†12.9 (±4.1)</td>
<td>12 hours</td>
</tr>
<tr>
<td>Plasma hs-CRP</td>
<td>0.49 (±.21)</td>
<td>†42.4 (±8.4)</td>
<td>24 hours</td>
</tr>
</tbody>
</table>

Clinical parameters and plasma levels of cytokines are presented as mean (±SD). IL-6=interleukin-6; TNF=tumor necrosis factor-alpha; hs-CRP=high-sensitivity C-reactive protein; *p<0.0001, †p<0.005
Table 3. Insulin Signaling Proteins are Modulated in Adipose and Whole Blood during Endotoxemia

<table>
<thead>
<tr>
<th>Gene</th>
<th>Adipose mRNA Expression</th>
<th>Blood mRNA Expression</th>
<th>Mixed Effects Model P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Maximal Percent Change</td>
<td>Time</td>
<td>ANOVA P-value</td>
</tr>
<tr>
<td>Insulin Receptor</td>
<td>-25%</td>
<td>12 hours</td>
<td>0.26</td>
</tr>
<tr>
<td>IRS-1*</td>
<td>-47%</td>
<td>4 hours</td>
<td>0.03</td>
</tr>
<tr>
<td>IRS-2</td>
<td>-25%</td>
<td>4 hours</td>
<td>0.36</td>
</tr>
<tr>
<td>IRS-3</td>
<td>ND</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>GLUT-4</td>
<td>-24%</td>
<td>12 hours</td>
<td>0.33</td>
</tr>
</tbody>
</table>

*IRS = insulin receptor substrate. ND = not detected.
Figure 1

A

1.0
0.8
0.6
0.4
0.2
0.0

-24 -16 -8 0 8 16 24

LPS

TNF (mg/dL)

B

60
40
20
0
-24 -16 -8 0 8 16 24

LPS

Data Control

-24 -16 -8 0 8 16 24

LPS

Cortisol (mcg/dL)

-24 -16 -8 0 8 16 24

LPS

Growth Hormone (mcg/dL)

-24 -16 -8 0 8 16 24

LPS

hs-CRP (mg/dL)

-24 -16 -8 0 8 16 24

LPS

Free Fatty Acid (µEq/L)

-24 -16 -8 0 8 16 24

LPS

* * *
Figure 2

A) S Value

Pre-endotoxin - 2 weeks
Post-endotoxin + 24 hours

B) AIRG Value

Pre-endotoxin - 2 weeks
Post-endotoxin + 24 hours

C) HOMA IR value

-24 hours LPS
-5 min LPS
+24 hours LPS

D) HOMA B value

-24 hours LPS
-5 min LPS
+24 hours LPS
Evoked adipose inflammation and insulin resistance in humans

Figure 3

A

![Graph showing IL-6 fold change over time with n=15](image)

B

![Graph showing MCP1 fold change over time with n=15](image)

C

![Graph showing TNF fold change over time with n=15](image)

![Graph showing CXCL10 fold change over time with n=10](image)

![Graph showing A20 fold change over time with n=17](image)

![Graph showing Ratio A20: beta-actin](image)

![Graph showing Ratio MCP1: beta-actin](image)

A20, MCP1, and Beta-actin images at Pre-LPS, +4h, +12h, and +24h
Figure 4

A

SOCS-1 fold change

n=12

LPS

B

SOCS-1 fold change

n=20

LPS

*
Figure 5

- **Insulin Receptor**: Phosphorylated AKT
- **Insulin Receptor Substrate-1**: GLUT-4
- **Phosphorylated AKT**: Beta-Actin
- **GLUT-4**: Pre-LPS +4h +12h +24h
- **Beta-Actin**: Pre-LPS +4h +12h +24h